Since the listing of 3 pharmaceutical stocks, the stock price has been eye-catching, with an increase of more than 200 times!

【Pharmaceutical network pharmaceutical stock market】Recently is the semi-annual report disclosure period of listed companies, data show that in the field of pharmaceutical biology, as of August 25, more than 280 pharmaceutical and biological companies have issued semi-annual reports, nearly 60% of the companies have achieved performance growth, and nearly 30 companies have doubled
their net profit attributable to the mother.

The performance of many companies in the first half of the year hit new highs, such as WuXi AppTec, Katazai and so on
.

According to the semi-annual reports of listed pharmaceutical companies, the stock price changes of related companies have also attracted the attention
of the industry.

Wind data shows that as of August 24, the stock prices of Yunnan Baiyao, China Biopharmaceuticals, Tablet Zai zhen, Hengrui and Changchun Gaoxin have all increased by more than 100 times since their listing, of which the stock prices of Yunnan Baiyao, China Biopharmaceuticals and Tablets have risen by more than 200 times
since their listing.

Yunnan Baiyao: Up to 422 times since its listing Yunnan Baiyao was listed on December 15, 1993, and its stock price has risen by 42,189% since its listing, and as of August 24, the company's market value reached 95.
5 billion yuan
.

The 2021 annual report disclosed that Yunnan Baiyao achieved operating income of 36.
374 billion yuan, an increase of 11.
09% year-on-year; Achieved a net profit of 2.
804 billion yuan, down 49.
17%
year-on-year.

Entering the first quarter of 2022, the company's revenue was about 9.
43 billion yuan, a year-on-year decrease of 8.
7%; Net profit was about 914 million yuan, an increase of 19.
81%
year-on-year.

According to the annual report, the current products of Yunnan Baiyao include pharmaceutical and medical equipment series, native medicinal materials and health care series, big health product series, and tea series
.

It is also understood that the company has successively laid out Beijing, Shanghai, Hainan, Hong Kong, South Korea and other regions at home and abroad in 2020, which means that the internationalization journey has been steadily opened, and the future will continue to do a good job in the four major business sectors of drugs, health products, traditional Chinese medicine resources, and provincial medicine, while making efforts to expand the fields of medical beauty and orthopedics, steadily promoting the industrial hemp business according to law, and actively seeking a breakthrough in
the new track.

China Biopharmaceuticals: 256 times up since listing China Biopharmaceuticals was listed on September 29, 2000, and its stock price has risen by 25649% since its listing, and as of August 24, the company's market value reached 62.
2 billion yuan
.

According to the 2021 annual report, the company achieved revenue of 26.
861 billion yuan, an increase of 13.
6% year-on-year; The net profit attributable to the mother was 14.
608 billion yuan, a year-on-year increase of 427.
2%.


According to the 2022 interim results report, the company's operating income in the first half of the year reached 15.
19 billion yuan, an increase of 5.
9% year-on-year; Attributable net profit reached 1.
66 billion yuan, an increase of 4.
5%
year-on-year.

According to the data, China's biopharmaceutical business covers the entire industrial chain
of pharmaceutical research and development platform, intelligent production and strong sales system.

Products include a variety of biological drugs and chemical drugs, involving liver disease, tumors, cardiovascular and cerebrovascular diseases, orthopedics, digestive system, anti-infection and respiratory diseases and other fields
.

Katazai: Nearly 222 times since its listing Katazai was listed on June 16, 2003, and its stock price has risen by 22182% since its listing, and as of August 24, the company's market value reached 174.
7 billion yuan
.

According to the 2021 annual report, during the reporting period, the company achieved operating income of 8.
022 billion yuan, an increase of 23.
20% year-on-year, and net profit of 2.
431 billion yuan, an increase of 45.
46%
year-on-year.

In the first half of this year, the company achieved a net profit attributable to the mother of 1.
314 billion yuan, an increase of 17.
85% year-on-year; The net profit after deduction of non-attributable to the mother was 1.
317 billion yuan, an increase of 18.
08%
year-on-year.

According to the data, Tablets is a Chinese medicine enterprise with "Tablets" as the main product, and the company has two dosage forms, lozenges and capsules, with the same ingredients and functions
.

As a pharmaceutical brand with a long history, the company has always adhered to the fine tradition of "taking virtue as a pharmaceutical and taking medicine to Hongde", taking quality as a "sharp weapon" and scientific research as a "heavy weapon", abiding by the mission and responsibility of state-owned enterprises, letting Katazai innovate in the inheritance, and composing a new chapter
in the high-quality development of modern Chinese medicine brands.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.